Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LipidA-LNP encapsulating FVIII plasmid
- Development stage
- Preclinical
- Lead developer
- Seattle Children's Research Institute
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LipidA-LNP encapsulating FVIII plasmid is a non-viral gene therapy candidate being developed for the treatment of Hemophilia A. It utilizes a proprietary lipid nanoparticle (LNP) platform featuring a novel lipid, LipidA (and its optimized version LipidAopt), to encapsulate a DNA plasmid (pCAG-FVIIIX10) encoding a secreted version of Coagulation Factor VIII. Unlike traditional viral vectors, this LNP-based DNA delivery system is designed to be re-dosable and avoid the constraints of pre-existing immunity to viral capsids. Preclinical studies in Hemophilia A mouse models have demonstrated sustained Factor VIII expression and the feasibility of re-administration to maintain therapeutic levels.
- Other names
- LipidA-LNP-pDNALipidA-LNP-pCAG-FVIIIX10LipidA-LNP-pCAG-FVIIIX-10LipidA-LNP-pCAG-FVIIIX 10
02
Targets
F10 (Factor Xa)BB-031 (Von Willebrand factor)Coagulation Factor IXa
Beyond the preview
Go deeper on LipidA-LNP encapsulating FVIII plasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LipidA-LNP encapsulating FVIII plasmid.